NOTICE: Thank you for visiting our site. Your experience is important to us. We're upgrading our system to better serve you. During this time, purchases and member logins will be unavailable. Full functionality will be restored by Monday, 29 July.
NOTICE: Thank you for visiting our site. Your experience is important to us. We're upgrading our system to better serve you. During this time, purchases and member logins will be unavailable. Full functionality will be restored by Monday, 29 July.
Sunday, 17 March | 1300–1800
Monday, 18 March | 0730–1830
Tuesday, 19 March | 0700–1700
Monday, 18 March | 1015–1815
Tuesday, 19 March | 1000–1515
Explore the exhibitor directory and schedule meetings, plus make sure to take advantage of the opportunities to connect with colleagues in the exhibit hall during the networking breaks.
Attend the Interactive Regulatory Panel to be part of an open discussion on global issues relevant to the aseptic industry and FDA.
Make the most of your professional development by attending in-depth training in 4 critical areas of pharma manufacturing, taking place 20–22 March.
We welcome your feedback throughout the year on ISPE's continuing education events. A survey will be emailed to all attendees at the close of the conference. Thank you for providing your feedback and ideas for future topics.
Follow the official hashtag of the 2019 ISPE Aseptic Conference #ISPEAseptic to stay up to date on what is going on throughout the conference, and use it to share your own experiences on social media.
The pharmaceutical industry stands at the cusp of a transformative era, where the integration of sustainability within the supply chain is not just a trend, but a necessity. The 2024 ISPE Annual Meeting &...
Although parenteral products make up only 1% of global pharmaceutical prescriptions by volume, at list price they now make up nearly half of global sales value, a percentage that has been increasing. Many of these are complex products produced in smaller batches for immunology or oncology, and a large majority are biologic therapies, which are generally poorly suited to oral formulations.
In 2020, CSL initiated a benchmarking activity with a small group of peer companies identified through ISPE to explore creation and maturation of asset management programs at each company. The initial sessions were a success, covering topics such as asset condition evaluations and asset management governance. CSL was keen to continue the conversations and gather more insights on certain...